Pharmaceutical News

RSS

Diabetes drug semaglutide shows promise in reducing dementia risk

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

24 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

New oral drug shows promise for type 2 diabetes and obesity without side effects

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

23 Jun 2025

Aspirin lowers diabetes risk during COVID-19, but not without side effects

A large real-world Italian cohort study found that daily low-dose aspirin use significantly lowered the risk of developing type 2 diabetes, especially during the COVID-19 pandemic. The protective effect appears linked to aspirin’s anti-inflammatory properties, though bleeding risks require caution.

19 Jun 2025

Why Alzheimer’s DNA tests don’t treat all populations equally

A major global study tested whether European-derived polygenic risk scores (PGS) for Alzheimer’s disease can predict risk across diverse populations. While PGS performed well in many groups, it was less accurate in individuals of sub-Saharan African and Indian ancestry, highlighting the urgent need for more inclusive genetic data.

19 Jun 2025

Full tumor DNA sequencing becomes standard for children with cancer

Readouts of the full DNA of children with cancer at diagnosis have been implemented as the standard of care in a European first.

19 Jun 2025

A revolutionary drug for extreme hunger offers clues to obesity’s complexity

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction.

16 Jun 2025

Non-prescribed ketamine use rises sharply across the UK

The rise in non-prescribed ketamine use across the UK in recent years is a cause for concern, say doctors in The BMJ today.

12 Jun 2025

Rutgers study challenges FDA warning on antiseizure drug

Rutgers Health researchers found that lamotrigine, a widely prescribed antiseizure medication, to be safe in older adults with epilepsy, contrary to a safety warning by the Food and Drug Administration (FDA).

11 Jun 2025

Chikungunya vaccine could stop millions of infections worldwide, study finds

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with up to 35 million infections annually. Strategic deployment of the IXCHIQ vaccine could prevent thousands of infections and deaths each year.

11 Jun 2025

AMA endorses resolution to expand access to anti-obesity medications

The American Medical Association (AMA) House of Delegates today passed the Endocrine Society's resolution to improve access to anti-obesity medications.

11 Jun 2025

Large cohort study reassures on mRNA vaccine safety for early pregnancies

A large prospective cohort study in Germany found no statistically significant increase in major birth defects following first trimester mRNA COVID-19 vaccination. While slightly higher rates of some anomalies were observed in vaccinated pregnancies, no consistent patterns or causal links emerged.

11 Jun 2025

Psilocybin rewires the brain for weeks, study finds

Psilocybin induces consistent and sustained changes in brain network connectivity, particularly between the hippocampus and default mode network, as shown using high-resolution fMRI in healthy adults. These neural effects, distinct from those produced by methylphenidate, may underlie the drug’s psychological benefits and were reproducible within individuals over time.

10 Jun 2025

Heart drug repurposed to kill hospital superbug Acinetobacter baumannii

A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few antibiotics available for treatment.

10 Jun 2025

Dr. Stephen Ross’s research into psychedelic medicine expands therapeutic frontiers

In a comprehensive Genomic Press Interview published today, Dr. Stephen Ross, a leading figure in psychedelic medicine at New York University (NYU), reveals how a serendipitous conversation in 2006 launched his journey into investigating psychedelic compounds as potential breakthrough treatments for some of psychiatry's most challenging conditions.

10 Jun 2025